Efficient inhibition of non-small-cell lung cancer xenograft by systemic delivery of plasmid-encoding short-hairpin RNA targeting VEGF

Cancer Biotherapy and Radiopharmaceuticals

Volumn 25, Issue 1, 2010, Pages 65-73

  Yang, Yang ^a   Bai, Yu ^b   Xie, Gang ^a   Zhang, Na ^a   Ma, Yong Ping ^a   Chen, Li Juan ^a   Jiang, Yu ^a   Zhao, Xia ^b   Wei, Yu Quan ^a   Deng, Hong Xin ^a  

^a SICHUAN UNIVERSITY   (China)

^b SICHUAN UNIVERSITY   (China)

Author keywords

Angiogenesis; Non small cell lung cancer (NSCL)Capoptosis; RNA interference; Vascular endothelial growth factor (VEGF)

Indexed keywords

CD31 ANTIGEN; CYCLINE; SHORT HAIRPIN RNA; VASCULOTROPIN; SMALL INTERFERING RNA;

ANGIOGENESIS; ANIMAL EXPERIMENT; ANIMAL MODEL; ANTINEOPLASTIC ACTIVITY; APOPTOSIS; ARTICLE; CANCER GROWTH; CANCER INHIBITION; CELL PROLIFERATION; CONTROLLED STUDY; DRUG EFFICACY; ENZYME LINKED IMMUNOSORBENT ASSAY; GENE SILENCING; GENETIC TRANSFECTION; HUMAN; HUMAN CELL; LUNG NON SMALL CELL CANCER; METASTASIS; MOLECULAR CLONING; MOUSE; NICK END LABELING; NONHUMAN; NUDE MOUSE; PLASMID; PRIORITY JOURNAL; PROTEIN EXPRESSION; REVERSE TRANSCRIPTION POLYMERASE CHAIN REACTION; RNA INTERFERENCE; TUMOR VOLUME; TUMOR XENOGRAFT; ADMINISTRATION AND DOSAGE; ANIMAL; ANTAGONISTS AND INHIBITORS; CARCINOMA, NON-SMALL-CELL LUNG; DRUG SCREENING; GENE THERAPY; GENETICS; LUNG NEOPLASMS; PROCEDURES;

ANIMALS; CARCINOMA, NON-SMALL-CELL LUNG; GENETIC THERAPY; HUMANS; LUNG NEOPLASMS; MICE; MICE, NUDE; PLASMIDS; RNA, SMALL INTERFERING; TRANSFECTION; VASCULAR ENDOTHELIAL GROWTH FACTORS; XENOGRAFT MODEL ANTITUMOR ASSAYS;

EID: 77649330574     PISSN: 10849785     EISSN: None     Source Type: Journal    
DOI: 10.1089/cbr.2009.0692     Document Type: Article

References (44)

1. Parkin DM, Bray F, Ferlay J, et al. Global cancer statistics, 2002. CA Cancer J Clin 2005;55:74.
2. Novello S, Le Chevalier T. Chemotherapy for non-small-cell lung cancer. Part 1: Early-stage disease. Oncology (Williston Park) 2003;17:357.
3. Folkman J. Role of angiogenesis in tumor growth and meta-stasis. Semin Oncol 2002;29(6 Suppl 16):15.
4. Robinson CJ, Stringer SE. The splice variants of vascular endothelial growth factor (VEGF) and their receptors. J Cell Sci 2001;114(Pt 5):853.
5. Gabrilovich D, Ishida T, Oyama T, et al. Vascular endothelial growth factor inhibits the development of dendritic cells and dramatically affects the differentiation of multiple hemato-poietic lineages in vivo. Blood 1998;92:4150.
6. Pidgeon GP, Barr MP, Harmey JH, et al. Vascular endothelial growth factor (VEGF) upregulates BCL-2 and inhibits apoptosis in human and murine mammary adenocarcinoma cells. Br J Cancer 2001;85:273.
7. Melder RJ, Koenig GC, Witwer BP, et al. During angiogen-esis, vascular endothelial growth factor and basic fibroblast growth factor regulate natural killer cell adhesion to tumor endothelium. Nat Med. 1996;2:992.
8. Ferrara N. Vascular endothelial growth factor: Basic science and clinical progress. Endocr Rev 2004;25:581.
9. Kaya A, Ciledag A, Gulbay BE, et al. The prognostic significance of vascular endothelial growth factor levels in sera of non-small-cell lung cancer patients. Respir Med 2004;98:632.
10. Yuan A, Yu CJ, Chen WJ, et al. Correlation of total VEGF mRNA and protein expression with histologic type, tumor angiogenesis, patient survival, and timing of relapse in nonsmall-cell lung cancer. Int J Cancer 2000;89:475.
11. Shimanuki Y, Takahashi K, Cui R, et al. Role of serum vascular endothelial growth factor in the prediction of angiogenesis and prognosis for non-small-cell lung cancer. Lung 2005;183:29.
12. Hannon GJ. RNA interference. Nature 2002;418:244.
13. Pai SI, Lin YY, Macaes B, et al. Prospects of RNA interference therapy for cancer. Gene Ther 2006;13:464.
14. Hannon GJ, Rossi JJ. Unlocking the potential of the human genome with RNA interference. Nature 2004;431:371.
15. Reich SJ, Fosnot J, Kuroki A, et al. Small interfering RNA (siRNA) targeting VEGF effectively inhibits ocular neovascularization in a mouse model. Mol Vis 2003;9:210.
16. Oka N, Soeda A, Inagaki A, et al. VEGF promotes tumori-genesis and angiogenesis of human glioblastoma stem cells. Biochem Biophys Res Commun 2007;360:553.
17. Du XB, Lang JY, Xu JR, et al. Vesicular stomatitis virus matrix protein gene enhances the antitumor effects of radi-ation via induction of apoptosis. Apoptosis 2008;13:1205.
18. Schiller JH, Harrington D, Belani CP, et al. Comparison of four chemotherapy regimens for advanced non-small-cell lung cancer. NE JM 2002;346:92.
19. Raben D, Helfrich B, Bunn PA, Jr. Targeted therapies for non-small-cell lung cancer: Biology, rationale, and preclini-cal results from a radiation oncology perspective. Int J Ra-diat Oncol Biol Phys 2004;59(2 Suppl):27.
20. Cristofanilli M, Charnsangavej C, Hortobagyi GN. Angiogenesis modulation in cancer research: Novel clinical approaches. Nat Rev Drug Discov 2002;1:415.
21. Bachelder RE, Crago A, Chung J, et al. Vascular endothelial growth factor is an autocrine survival factor for neuropilinexpressing breast carcinoma cells. Cancer Res 2001;61:5736.
22. Jackson MW, Roberts JS, Heckford SE, et al. A potential autocrine role for vascular endothelial growth factor in prostate cancer. Cancer Res 2002;62:854.
23. Tian X, Song S, Wu J, et al. Vascular endothelial growth factor: Acting as an autocrine growth factor for human gastric adenocarcinoma cell MGC803. Biochem Biophys Res Commun 2001;286:505.
24. Giaccone G. The potential of antiangiogenic therapy in nonsmall-cell lung cancer. Clin Cancer Res 2007;13:1961.
25. Presta LG, Chen H, O'Connor SJ, et al. Humanization of an antivascular endothelial growth factor monoclonal antibody for the therapy of solid tumors and other disorders. Cancer Res 1997;57:4593.
26. Shaheen RM, Davis DW, Liu W, et al. Antiangiogenic therapy targeting the tyrosine kinase receptor for vascular endothelial growth factor receptor inhibits the growth of colon cancer liver metastasis and induces tumor and endothelial cell apoptosis. Cancer Res 1999;59:5412.
27. Holash J, Davis S, Papadopoulos N, et al. VEGF-Trap: A VEGF blocker with potent antitumor effects. Proc Natl Acad Sci U S A 2002;99:11393.
28. Goldman CK, Kendall RL, Cabrera G, et al. Paracrine expression of a native soluble vascular endothelial growth factor receptor inhibits tumor growth, metastasis, and mortality rate. Proc Natl Acad Sci U S A 1998;95:8795.
29. Cao Y. Endogenous angiogenesis inhibitors and their therapeutic implications. Int J Biochem Cell Biol 2001;33:357.
30. Ferrara N. VEGF as a therapeutic target in cancer. Oncology 2005;69(Suppl 3):11.
31. Kong HL, Crystal RG. Gene therapy strategies for tumor antiangiogenesis. J Natl Cancer Inst 1998;90:273.
32. Nabel GJ, Nabel EG, Yang Z-Y, et al. Direct gene transfer with DNA-liposome complexes in melanoma: Expression, biologic activity, and lack of toxicity in humans. PNAS 1993;90:11307.
33. Guan H, Zhou Z, Wang H, et al. A small interfering RNA targeting vascular endothelial growth factor inhibits Ewing's sarcoma growth in a xenograft mouse model. Clin Cancer Res 2005;11:2662.
34. Mulkeen AL, Silva T, Yoo PS, et al. Short interfering RNA-mediated gene silencing of vascular endothelial growth factor: Effects on cellular proliferation in colon cancer cells. Arch Surg 2006;141:367; discussion, 374.
35. Guo Y, Guo H, Zhang L, et al. Genomic analysis of anti-hepatitis B virus (HBV) activity by small interfering RNA and lamivudine in stable HBV-producing cells. J Virolo 2005;79:14392.
36. Zhdanov RI, Podobed OV, Vlassov VV. Cationic liposome-DNA complexes-lipoplexes for gene transfer and therapy. Bioelectrochemistry 2002;58:53.
37. Young LS, Mautner V. The promise and potential hazards of adenovirus gene therapy. Gut 2001;48:733.
38. Jiao X, Wang RY, Qiu Q, et al. Enhanced hepatitis C virus NS3 specific Th1 immune responses induced by codelivery of protein antigen and CpG with cationic liposomes. J Gen Virol 2004;85(Pt 6):1545.
39. Zelphati O, Szoka FC, Jr. Mechanism of oligonucleotide re-lease from cationic liposomes. Proc Natl Acad Sci U S A 1996;93:11493.
40. Sangare L, Morisset R, Omri A, et al. Incorporation rates, stabilities, cytotoxicities, and release of liposomal tetracy-cline and doxycycline in human serum. J Antimicrob Che-mother 1998;42:831.
41. Webb MS, Harasym TO, Masin D, et al. Sphingomyelin-cholesterol liposomes significantly enhance the pharmaco-kinetic and therapeutic properties of vincristine in murine and human tumour models. Br J Cancer 1995;72:896.
42. Yuan F, Dellian M, Fukumura D, et al. Vascular permeability in a human tumor xenograft: Molecular size dependence and cutoff size. Cancer Res 1995;55:3752.
43. Simberg D, Weisman S, Talmon Y, et al. DOTAP (and other cationic liposomes): Chemistry, biophysics, and transfection. Crit Rev Ther Drug Carrier Syst 2004;21:257.
44. Tousignant JD, Gates AL, Ingram LA, et al. Comprehensive analysis of the acute toxicities induced by systemic administration of cationic liposome:plasmid DNA complexes in mice. Hum Gene Ther 2000;11:2493.